VistaGen Therapeutics (VTGN)
(Delayed Data from NSDQ)
$4.76 USD
+0.06 (1.28%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $4.78 +0.02 (0.42%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VTGN 4.76 +0.06(1.28%)
Will VTGN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for VTGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VTGN
Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?
Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?
VTGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Vistagen (VTGN) Stock Stands Out in a Strong Industry
Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
Other News for VTGN
7 Stocks Under $15 Predicted to Boom in the Next 2 Years
Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027
Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
Biotech Alert: Searches spiking for these stocks today
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2